Epidermal growth factor receptor (EGFR) is involved in cell proliferation leading to malignant transformation, and for that it is considered a therapeutic target for treatment and prevention in lung and other cancers.
Katholieke Universiteit Leuven and Springworks Therapeutics Inc. have jointly identified tetrahydropyridopyrimidines acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) or WW domain-containing transcription regulator protein 1 (WWTR1; TAZ)/TEAD interaction inhibitors.
A Retune Pharma Inc. patent describes new insulin-like growth factor 1 receptor (IGF-1R; CD221) inhibitors reported to be useful for the treatment of cancer, thyroid-associated ophthalmopathy (Graves ophthalmopathy) and autoimmune disease.
CCM Biosciences Inc. has launched with a focus on discovering and developing novel drugs, including small molecules, gene therapies, biologics and nanomedicines, and companion diagnostic tests.
Arvinas Operations Inc. has reported the development of diacylglycerol kinase α (DGK-α; DGKA) inhibitors reported to be useful for the treatment of cancer.
Nerio Therapeutics Inc. has patented new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors reported to be useful for the treatment of cancer, diabetes type 2, obesity and metabolic diseases.
RSS
